1-20 of 286
ixazomib
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Up-front ixazomib in older patients with myeloma

Jean-Luc Harousseau, Mohamad Mohty
Journal: Blood
Blood (2021) 137 (26): 3584–3586.
DOI: https://doi.org/10.1182/blood.2021011262
Published: 2021
Journal Articles

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

Clinical Trials & Observations
Thierry Facon, Christopher P. Venner, Nizar J. Bahlis, Fritz Offner, Darrell J. White, Lionel Karlin, Lotfi Benboubker, Sophie Rigaudeau, Philippe Rodon, Eric Voog, Sung-Soo Yoon, Kenshi Suzuki, Hirohiko Shibayama, Xiaoquan Zhang, Philip Twumasi-Ankrah, Godwin Yung, Robert M. Rifkin, Philippe Moreau, Sagar Lonial, Shaji K. Kumar, Paul G. Richardson, S. Vincent Rajkumar
Journal: Blood
Blood (2021) 137 (26): 3616–3628.
DOI: https://doi.org/10.1182/blood.2020008787
Published: 2021
Includes: Supplemental data
Journal Articles

Sanchorawala V, Palladini G, Kukreti V, et al. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 2017;130(5):597-605.

Journal: Blood
Blood (2020) 135 (13): 1071.
DOI: https://doi.org/10.1182/blood.2020005086
Published: 2020
Journal Articles

Progressive Multifocal Leukoencephalopathy in a Patient with Multiple Myeloma Receiving Daratumumab and Pomalidomide

Jorge Monge, MD, Jorge Contreras, MD, Sarah Elsoukkary, MD, Jin Guo, MD, Art Perry, PA, Robin S. Solomon, Kari Flicker, BS, David S Jayabalan, MSc, Morton Coleman, MD, Adriana C. Rossi, MDMSc, Rebecca Harris, MD, Markus Plate, MD, Joerg-Patrick Stuebgen, MB, ChB, MD, Ruben Niesvizky, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4876.
DOI: https://doi.org/10.1182/blood-2019-122134
Published: 2019
Journal Articles

Treatment Patterns in Patients (pts) with Refractory/Relapsed Multiple Myeloma (RRMM) in Germany between 2016 and 2018

Maximilian Merz, Vishal Patel, Lucie Kutikova, PhD, Andrea Lebioda, Martina Schoehl, Lenka Kellermann, BS, MBA, Hartmut Goldschmidt, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4734.
DOI: https://doi.org/10.1182/blood-2019-128030
Published: 2019
Journal Articles

Cost Effectiveness of Novel Agents in the Treatment of Multiple Myeloma: A Systematic Review

Sarah Perry, MD MSc, Sylvia McCulloch, MD MSc
Journal: Blood
Blood (2019) 134 (Supplement_1): 4738.
DOI: https://doi.org/10.1182/blood-2019-125454
Published: 2019
Journal Articles

A Phase I/II Study of Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: PrE0404

Jonathon B. Cohen, MDMS, Craig A. Portell, MD, Mehdi Hamadani, MD, Opeyemi Jegede, PhD, Catherine Diefenbach, MD, Kevin A. David, MD, Christopher D. Fletcher, MD, Daniel J. Landsburg, MD, Brad S. Kahl, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1541.
DOI: https://doi.org/10.1182/blood-2019-127494
Published: 2019
Journal Articles

Effect and Safety of Ixazomib Plus Dexamethasone (ID) in Patients with Waldenstrom's Macroglobulinemia (WM): Real-World Evidences from a Single Center in China

Jiadai Xu, Zheng Wei, MD, Jing Li, MD, Jingli Zhuang, Lili Ji, Peng Liu, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5265.
DOI: https://doi.org/10.1182/blood-2019-128816
Published: 2019
Journal Articles

Targeting MDM2 and XIAP By Idasanutlin in Diffuse Large B-Cell Lymphoma

Juan J. Gu, MD PhD, Samuel J. Thompson, Cory Mavis, MSc, Matthew J. Barth, MD, Pallawi Torka, MD, Francisco J. Hernandez-Ilizaliturri, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5301.
DOI: https://doi.org/10.1182/blood-2019-129009
Published: 2019
Journal Articles

Bortezomib Overcomes Poor Prognosis Conferred By High Sictp in Untreated Plasma Cell Disorders

Akira Honda, MD PhD, Yu Oyama, MD, Kazuhiro Toyama, MD PhD, Mineo Kurokawa, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5492.
DOI: https://doi.org/10.1182/blood-2019-129324
Published: 2019
Journal Articles

In silico Prediction Followed By in Vitro validation Identifies the Survivin Inhibitor YM155 As a Potent Secondary Drug Against Pi-Resistant Myeloma

Harish Kumar, PhD, Ujjal Kumar Mukherjee, PhD, Li Chen, PhD, Amit Kumar Mitra, PhD MSc, BSc
Journal: Blood
Blood (2019) 134 (Supplement_1): 5543.
DOI: https://doi.org/10.1182/blood-2019-131923
Published: 2019
Journal Articles

Real-World Data on Safety and Efficacy of Venetoclax-Based Regimens in Relapsed/Refractory t[11;14] Multiple Myeloma

Diana Basali, MD, Rajshekhar Chakraborty, MD, Lisa Rybicki, MS, Nathaniel Rosko, PharmD, Janice Reed, RN, Mary Ann Karam, RN, Kristen Schlueter, RN, Hayley Dysert, Beth M. Faiman, PhDCNP, Kimberly Hamilton, APRN/PA, Matt Kalaycio, MD, Jason Valent, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5566.
DOI: https://doi.org/10.1182/blood-2019-129002
Published: 2019
Journal Articles

Advancements in Treatment for Newly Diagnosed Frail and Elderly Myeloma Patients: A Systematic Review

Syed Maaz Abdullah, MBBS, Tariq Iqtidar Sadiq Syed, MD, Muhammad Salman Faisal, MD MBBS, Awais Ijaz, MD, Syeda Sabeeka Batool, MBBS, MD, Muhaddis Ejaz Ahmad, MD, Muhammad Abdullah Yousaf, MBBS, MD, Saif Ur Rehman, MBBS, MD, Maaz Ahmed Yusufi, MD, Sravanthi Kotapati, MBBS, Maimoona Khan, MBBS, Asma Waheed, MBBS, Khadija Zia Zaidi, MBBS, Sikander Abdullah, MBBS, Faiz Anwer, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5589.
DOI: https://doi.org/10.1182/blood-2019-128892
Published: 2019
Journal Articles

The Efficacy and Safety Profile of Ixazomib-Based Regimens in Patients with Relapsed/Refractory Multiple Myeloma in Routine Clinical Practice: Real World Data from a Multi-Center Study in China

Jing Li, MD, Li Bao, Zhong-jun Xia, MD, Kaiyang Ding, Bingzong Li, MD PhD, Bing Chen, Zhengzheng Fu, Sili Wang, Wenhao Zhang, MD PhD, Xin Zhou, Luoming Hua, PhD, Wei Yang, Luo Jun, Liang Wang, Tianhong Xu, Yang Yang, Weida Wang, MD, Guolin Wu, Yun Huang, Peng Liu, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5592.
DOI: https://doi.org/10.1182/blood-2019-130040
Published: 2019
Journal Articles

Retrospective Analysis of the Efficacy of Triplet Therapy, Including Lenalidomide, in Newly Diagnosed Multiple Myeloma Patients Who Obtained Responses Less Than VGPR after Rd Therapy

Naoki Takezako, MD PhD, Naoya Kaneko, MD, Airi Hamano, Ph, Kenichi Ito, MD, Naohiro Sekiguchi, MD, Satoshi Noto, MD, Takanori Teshima, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5595.
DOI: https://doi.org/10.1182/blood-2019-131617
Published: 2019
Journal Articles

Three Drug Regimens for Newly Diagnosed Multiple Myeloma Transplant-Ineligible Elderly Patients - a Systematic Review

Abdul Aziz Siddiqui, MD, Kazi Najamus-saqib Khan, Arafat Ali Farooqui, MD, Muhammad Saad Farooqi, MD, Muhammad Junaid Tariq, MD, Faiz Anwer, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5574.
DOI: https://doi.org/10.1182/blood-2019-132095
Published: 2019
Journal Articles

Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (Ixa Dara dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim Efficacy Analysis of the Phase II HOVON 143 Study

Claudia A.M. Stege, MD, Kazem Nasserinejad, Ellen van der Spek, MD PhD, Roel J.W. Van Kampen, MD PhD, Maaike Sohne, MD, Noortje Thielen, MD PhD, Yavuz Bilgin, MD PhD, Esther G.M. De Waal, MD, Inge Ludwig, MD MSc, Maria B.L. Leijs, MD, Alain Kentos, MD, Gert Jan Timmers, MD PhD, Koen de Heer, MD, Matthijs Westerman, MD, Marie Christiane Vekemans, Nazik Durdu-Rayman, MD, Nicole C.H.P. van der Burg-de Graauw, MD, Niels W. C. J. Van De Donk, MD PhD, Pieter Sonneveld, Saskia K. Klein, MD PhD, Mark-David Levin, MD PhD, Sonja Zweegman, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 695.
DOI: https://doi.org/10.1182/blood-2019-121694
Published: 2019
Journal Articles

Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial

Ravi Vij, MBBS, Thomas G. Martin, III, MD, Nitya Nathwani, MD, Mark A. Fiala, BS, Feng Gao, PhD, Abhinav Deol, MD, Francis K. Buadi, MB, CHB, Jonathan L. Kaufman, MD, Craig C Hofmeister, MDMPH, Tara K. Gregory, MD, Jesus G. Berdeja, MD, Ajai Chari, MD, Ashley E. Rosko, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 602.
DOI: https://doi.org/10.1182/blood-2019-130644
Published: 2019
Journal Articles

Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Mark Bustoros, MD, Omar Nadeem, MD, Adam S Sperling, MD PhD, Giada Bianchi, MD, Lily Ardente, BS, Robert A. Redd, MS, Julia Prescott, NP, Erin Frey, RN, Kathleen Guimond, RN, Rachel Styles, BS, Kalvis Hornburg, BA, Alexandra Savell, BS, Nang Kham Su, BA, Govind Bindra, BA, Cody J Boehner, BS, Kaitlen Reyes, DNP, Houry Leblebjian, PharmD, Diane Warren, Nikhil C. Munshi, MD, Jacob P. Laubach, MD, Kenneth C. Anderson, MD, Paul G. Richardson, MD, Irene M. Ghobrial, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 580.
DOI: https://doi.org/10.1182/blood-2019-128519
Published: 2019
Journal Articles

High Rates of Venous and Arterial Thrombotic Events in POEMS Patients: Results from the UK-Based POEMS Registry, Highlighting the Need for Therapeutic Guidelines

Zara Sayar, MD FRCPath, MRCP, Anna Weatherill, Stephen Keddie, Jonathan Sive, MD, Michael P Lunn, Mari Thomas, Shirley D'Sa
Journal: Blood
Blood (2019) 134 (Supplement_1): 714.
DOI: https://doi.org/10.1182/blood-2019-125639
Published: 2019